

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 December 2005 (29.12.2005)

PCT

(10) International Publication Number
WO 2005/123074 A1

(51) International Patent Classification:
A61K 31/44 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:
PCT/GB2004/002330

(22) International Filing Date: 1 June 2004 (01.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0312419.5 30 May 2003 (30.05.2003) GB

(71) Applicant (for all designated States except US): **BOOTS
HEALTHCARE INTERNATIONAL LIMITED**
[GB/GB]; 1 Thane Road West, Nottingham NG2 3AA
(GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUNDERRAJ,
Palaniswamy** [IN/CH]; Bachsstrasse 11, CH-8162 Stein-
mur (CH). **SHEPHARD, Adrian** [GB/GB]; 44 Leicester
Street, Long Eaton, Nottingham NG10 1FJ (GB). **JONES,
Huw** [GB/GB]; 34 Archer Crescent, Wollaton, Notting-
ham NG8 1HB (GB).

(74) Agents: **WALSH, David, Patrick et al.**; Appleyard Lees,
15 Clare Road, Halifax HX1 2HY (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:
14 December 2006

(15) Information about Correction:
see PCT Gazette No. 50/2006 of 14 December 2006

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS

(57) Abstract: There is disclosed the use of triprolidine, in combination with at least one further active pharmaceutical agent, for enabling an individual to wake refreshed after sleep and the method of treating such an individual with triprolidine. Use of triproli-
dine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition
for the treatment of sleep disorders is also described. A method of treating sleep of a person suffering from a sleep disorder, which
method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical
agent, as active ingredient to such a person is also described. The triprolidine is administered shortly before a person wishes to fall
asleep, preferably orally and most commonly in the form of a tablet containing up to 20mg, e.g. 0.1mg, 1.25mg or 2.5mg, of the
active ingredient. The triprolidine is also effective in enabling an individual to sleep more easily.

WO 2005/123074 A1

USE OF A COMPOUND IN THE TREATMENT OF SLEEP DISORDERS

The invention relates to a novel use of a known compound, in particular to the use of that compound in combination with at least one further active pharmaceutical agent in the treatment of sleep disorders experienced by a person,
10 whatever the cause of those disorders.

The present invention also relates to a method for the treatment or prevention of grogginess, drowsiness or lethargy on waking from sleep, to the use of triprolidine
15 in combination with at least one further active pharmaceutical agent as an aid to waking refreshed and to the use of triprolidine in combination with at least one further active pharmaceutical agent as both a sleep aid and a means to wake refreshed thereafter.

20 Although much is known about the use of various pharmaceutical sleeping formulations as aids to sleeping, little has been published about the possibility of a sleep aid enabling an individual to wake refreshed as opposed to
25 merely experiencing degrees of hangover effects such as grogginess, drowsiness, lethargy, etc.

Many people experience, either on an occasional or chronic basis, difficulty in achieving a satisfactory amount of
30 sleep. Such a problem may be attributable to external factors, such as factors causing stress or anxiety, to excessive use or misuse of stimulants (such as caffeine) or depressants (e.g. alcohol), or to temporary disturbance of the person's lifestyle, e.g. occasioned by shift-
35 working or long-haul travel through different timezones. Difficulty in sleeping may also be caused by chronic pain,

e.g. pain caused by sciatica, etc. Whatever the cause, the condition may be generally considered to be a sleep disorder and may commonly be referred to as "insomnia". It may manifest as difficulty in falling asleep and/or
5 wakefulness during the desired period of sleep, leading to a shortened duration of sleep and/or disruption of the normal pattern of sleep.

The result of these difficulties will commonly be fatigue
10 during the period of wakefulness, which may itself lead to stress and exacerbate the problem.

Various products are available to assist a user in overcoming problems of the type described above. Such
15 products, commonly called "sleeping pills" may, however, suffer from disadvantageous side-effects. For example, while the products may be effective in sending a user to sleep, their effect may be of short duration, resulting in premature wakening. In other cases, the user may achieve
20 the desired length of sleep but may awake with feelings of grogginess (a "hangover" effect). Such products may also be addictive. Tolerance may also develop to the drug which results in a decrease in effectiveness.

25 In other circumstances, a person may not suffer from sleep disorders as such, but may simply wish to achieve a particularly good night's sleep. In other words, the use of such products may be elective, rather than necessitated by a clinical need.

30

In addition to this well documented problem, many people also experience difficulties on waking such as grogginess, lethargy and drowsiness; difficulty in becoming fully alert and an absence of feeling refreshed. These
35 phenomena are not necessarily linked to the number of hours sleep or always encountered as a result of drugs taken prior to sleep such as alcohol, medication, etc.

Furthermore, individuals encountering tiredness during waking hours and other individuals having difficulty with insomnia resort to sleep aids in an attempt to increase or improve sleeptime rest. Nevertheless, it is also well
5 documented that a negative side effect of sleep aids can also be an increased feeling of grogginess on waking.

Triprolidine, (E)-2-[1-(4-methylphenyl-3-(1-pyrrolidinyl)-1-propenyl]pyridine, is a first generation anti-histamine
10 and has been marketed alone and, in combination with pseudoephedrine (a decongestant), for the treatment of allergic rhinitis. Triprolidine is known to have sedative effects and has been shown to have an adverse effect on the cognitive functions of users. These are undesirable
15 side-effects for an anti-histamine and may account for the limited extent to which triprolidine has been used in clinical practice. More recently-developed, second generation anti-histamines are less prone to such side effects, and most recent studies involving triprolidine
20 have used that compound as a positive control against which the more modern anti-histamine compounds have been compared. Such studies have generally been conducted using healthy volunteers following day time dosing, rather than persons suffering from any form of sleep disorder,
25 and have been concerned with the effects of the drug on day-time performance.

One study is known to have investigated the effect of triprolidine (amongst other anti-histamines) on sleep
30 directly (Nicolson et al, *Neuropharmacology* (1985) 24, 3, 245-250). In that study single doses of triprolidine (10mg or 20mg sustained release) were given at bedtime to volunteers. It was found that triprolidine did not significantly alter "sleep onset latency" (i.e. the time
35 required to fall asleep) compared with placebo. It was also found that, compared with placebo, triprolidine had no effect on wakefulness during sleep or total sleep time.

It has now been found that, contrary to what might have been expected in the light of previous studies, triprolidine can be used for inducing, prolonging or
5 enhancing sleep, and that its use is accompanied by important benefits in comparison with other compounds known for this purpose that could not have been predicted.

It has also been found that triprolidine surprisingly
10 increases the level of refreshedness felt upon waking if taken before sleeping. Advantageously, this effect is observed whilst triprolidine also acts as a sleep aid in facilitating the onset of stage I sleep and whilst enhancing sleep.

15 The increased level of refreshedness felt upon waking after taking triprolidine prior to sleeping was not expected and there has been no known disclosure of such an effect previously encountered.

20 In many medical conditions, lack of sleep is experienced as a side effect or direct symptom of the medical condition. Often, a patient with such a condition will be prescribed sleep aids as well as being treated for the
25 specific medical condition.

According to a first aspect of the present invention there is provided the use of triprolidine or a salt or hydrate thereof, in combination with at least one further active
30 pharmaceutical agent, as active ingredient of an aid to waking refreshed after sleeping.

According to a second aspect of the present invention there is provided the use of triprolidine or a salt or
35 hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient for the

preparation of a composition for enabling an individual to wake refreshed after sleeping.

According to a third aspect of the present invention there is provided the use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient for the preparation of a medicament for enabling an individual to wake refreshed after sleeping.

10

According to a fourth aspect of the present invention there is provided the use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, for the preparation of a sleep aid which also enables an individual to wake refreshed after sleeping.

According to a fifth aspect of the present invention there is provided the use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient of a sleep aid which also enables an individual to wake refreshed after sleeping.

According to a sixth aspect of the present invention there is provided the use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient for the preparation of a medicament for the treatment or prevention of a sleep disorder which also enables an individual to wake refreshed after sleeping.

According to a seventh aspect of the present invention there is provided a method for the treatment or prevention of grogginess, drowsiness or lethargy on waking from sleep in a mammal comprising the administration to the mammal in need thereof of a non-toxic effective dose of triprolidine

or a salt or hydrate thereof in combination with at least one further active pharmaceutical agent prior to the desired sleeping time.

5 According to an eighth aspect of the present invention there is provided a method for enabling an individual to wake refreshed after sleeping comprising the administration to the individual in need thereof and prior to the desired sleeping time of a non-toxic effective dose
10 of triprolidine or a salt or hydrate thereof in combination with at least one further active pharmaceutical agent.

According to a ninth aspect of the present invention there
15 is provided a method for aiding an individual's sleep and for also enabling the individual to subsequently wake refreshed after sleeping comprising the administration to the individual in need thereof and prior to the desired sleeping time of a non-toxic effective dose of
20 triprolidine or a salt or hydrate thereof in combination with at least one further active pharmaceutical agent.

According to a tenth aspect of the present invention there is provided a waking refreshed aid comprising triprolidine
25 or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient in association with a pharmaceutically acceptable carrier therefor and instructions for administration thereof at or just before the desired
30 sleeping time.

According to an eleventh aspect of the present invention there is provided a pharmaceutical formulation for the treatment or prevention of grogginess, drowsiness or
35 lethargy on waking after sleeping, comprising triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active

ingredient in association with a pharmaceutically acceptable carrier therefor and instructions for administration thereof at or just before the desired sleeping time.

5

According to a twelfth aspect of the present invention there is provided a pharmaceutical formulation for enabling an individual to wake more refreshed after sleeping, comprising triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient in association with a pharmaceutically acceptable carrier therefor and instructions for administration thereof at or just before the desired sleeping time.

15

According to a thirteenth aspect of the present invention there is provided a method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient to such a person.

According to a fourteenth aspect of the present invention, there is provided the use of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders.

According to a fifteenth aspect of the invention, there is provided a method for inducing, prolonging and/or enhancing sleep, which method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient to a person desirous of achieving sleep.

In a related aspect of the invention, there is provided the use of triprolidine as active ingredient thereof in combination with at least one further active pharmaceutical agent in the manufacture of a composition
5 for inducing, prolonging and/or enhancing sleep.

The invention extends to a kit comprising a first pharmaceutically active dosage form having triprolidine as the active agent, a second pharmaceutically active dosage
10 form and instructions on how to administer the said first and second dosage forms.

The said first and second dosage forms may be located in separate compartments of a pharmaceutical pack.
15

The said dosage forms may be combined into a combined dosage form for simultaneous administration.

Preferably, the said at least one further active
20 pharmaceutical agent is intended to be used in the treatment of a condition having sleep disorder as a symptom or potential symptom.

Preferably, the said further active pharmaceutical agent
25 may include, without limitation, antacids, analgesics, anti-inflammatories, antibiotics, laxatives, anorexics, antivirals, antiasthmatics, antidiuretics, antiflatulents, antimigraine agents, antispasmodics, additional sedatives, antihyperactives, tranquilizers, antihistamines,
30 decongestants, betablockers, antidepressives, hormones and combinations thereof. More preferably, the further active pharmaceutical agent is an active agent for treatment of pain, allergic conditions, migraine, coughing, a cold, flu, viral infections, throat infection, stress.

35

Preferably, the said further active pharmaceutical agent is independently intended for use as a, or in the

treatment of pain, allergic reactions, migraines, coughs, anaesthetics, antiviral agents, disinfectant, anxiety, decongestant or women's health (such as menopausal or period problems).

5

Preferably, the said at least one further active pharmaceutical agent is independently selected from: an active agent used in the treatment of pain relief, migraines, allergies, colds, flu, coughs, anxiety, or
10 women's health; an active agent used as an anaesthetic, antiviral agent, decongestant or disinfectant.

More preferably, the active agent is selected from an active agent used in the treatment of pain relief,
15 allergies, anxiety, migraines, colds, flu, coughs and as a decongestant or antiviral agent.

Most preferably, the active agent is selected from an agent used in the treatment of colds, coughs, pain relief
20 and flu.

Preferably, the said at least one further active agent is independently selected from a group consisting of
Ibuprofen, Fluribiprofen, Ketoprofen, aspirin,
25 Paracetamol, Aceclofenac, Codeine, Naproxen, Indomethacin, Diclofenac, Cox II, Meloxicam, Nitric oxide, Caffeine, Acrivastine, Cetirizine, Loratadine, Fexofenadine, Terfenadine, Beclomethasone, Hydrocortisone, Triptans, Almotriptan, Rizatriptan, Naratriptan, Sumatriptan,
30 Zolmatriptan, Domperidone, Acetylcysteine, Menthol, Ambroxol, Carbocisteine, Dextromethorphan, Guaiphenesin, Ipecacuanha, Phenylpropanolamine, Liquorice, Marshmallow, Squill, Honey, Glycerine, Aniseed, Benzocaine, Lidocaine, Amantadine, Aciclovir, Famciclovir, Ganciclovir,
35 Rimantadine, Penciclovir, Tribavirin, Valaciclovir, Neuraminidase inhibitors, Zanamir, Oseltamir, Benzalkonium chloride, Cetylpyridinium chloride, Dichlorobenzyl alcohol

(dcba), Amylmetacresol(amc), Dequalinium chloride, Hexylresorcinol, Eucalyptus oil, Thymol, Calamine, Propranolol, Chamomile, Hops, Passion flower, Valarian, Melatonin, Eucalyptus, Phenylephrine, Pseudoephedrine,
5 Cranberry and Bisphosphonates or a pharmaceutically acceptable salt of any of the foregoing.

A more preferred range of active agents is independently selected from a group consisting of Ibuprofen,
10 Fluribiprofen, Cox II such as meloxicam, triptans, Domperidone, Ambroxol, Dextromethorphan, Guaiphenesin, Lidocaine, Amantadine, Hexylresorcinol, dcba, amc, Propranolol, pseudoephedrine and Bisphosphonates or a pharmaceutically acceptable salt of any of the foregoing.

15 Optionally, the further active pharmaceutical agent may be combined with triprolidine in a single dosage form or in a pharmaceutical pack containing at least two dosage forms, one being triprolidine and the other being the said
20 further active pharmaceutical agent. Preferably, the said pack includes instructions on how to take and/or mix the combination of triprolidine with the said further active pharmaceutical agent.

25 Preferably, the dosage of the said further pharmaceutically active agent is one suitable for the treatment selected. Preferably, a single dosage form of said pharmaceutically active agent is in the range 0.1mg - 2000mg, more preferably, 0.2mg -1000mg, most preferably,
30 0.5mg -1000mg.

Typically, the dosage form for a pharmaceutical active in the treatment of pain is in the range 1-2000 mg, more preferably, 5-1000 mg depending upon the suitable dose
35 level of the further active pharmaceutical agent.

Typically, the dosage form for a pharmaceutical active in the form of triptans is in the range 0.1-200 mg, more preferably, 0.5-100 mg depending upon the suitable dose level of the further active pharmaceutical agent.

5

Typically, the dosage form for a pharmaceutical active in the treatment of viral infections is in the range 1-1000 mg, more preferably, 50-300 mg depending upon the suitable dose level of the further active pharmaceutical agent.

10

Typically, the dosage form for a pharmaceutical active in the treatment of allergies is in the range 0.1-500 mg, more preferably, 0.5-200 mg depending upon the suitable dose level of the further active pharmaceutical agent.

15

Typically, the dosage form for a pharmaceutical active in the treatment of coughs and colds is in the range 0.1-500 mg, more preferably, 1-200 mg depending upon the suitable dose level of the further active pharmaceutical agent.

20

Typically, the dosage form for a pharmaceutical active in the treatment of upper respiratory tract problems is in the range 0.1-100 mg, more preferably, 0.5-50 mg depending upon the suitable dose level of the further active pharmaceutical agent.

25

Typically, the dosage form for a pharmaceutical active in the treatment of anxiety is in the range 0.1-200 mg, more preferably, 1-100 mg depending upon the suitable dose level of the further active pharmaceutical agent.

30

It will also be understood that the term "inducing, prolonging and/or enhancing sleep" may encompass the treatment of a sleep disorder, i.e. a difficulty in achieving satisfactory sleep due to some internal or external factor, e.g. pain, stress or anxiety, misuse of stimulants or depressants, or temporary disturbance of

35

lifestyle. Alternatively, it may encompass elective desires on the part of a user to achieve a particularly beneficial period of sleep. Such a desire may, for instance, arise in anticipation of important events the following day for which a person may wish to be fully alert and refreshed. In any event, the term "sleep disorder" as used herein should be taken to independently include any one or more of the foregoing and, specifically, any objective or subjective difficulty in an individual in any one or more of the following:-

- getting to sleep, especially stage 1 sleep
- staying asleep
- sleeping well
- 15 - waking refreshed
- waking alert
- keeping awake
- keeping alert
- keeping refreshed
- 20 - performing well the next day

The present invention also extends to the use of triprolidine as a sleep aid. By definition, a sleep aid extends to use by a healthy individual who elects for a sleep aid, for example, before an important event. The term "sleep aid" as used herein includes any one or more of the following benefits:-

- faster onset to stage 1 sleep
- 30 - increasing duration of sleep periods
- decreasing the number and duration of awakenings
- increasing total duration of sleep
- increasing probability of sleeping well
- improving insomnia, especially chronic or mild-
- 35 moderate insomnia
- decreasing disturbances during sleeptime
- improving quality of sleep,

- as determined by any standard or known subjective or objective measures, for instance the Karolinska scale, Loughborough sleep log, Leeds sleep evaluation questionnaire or actimetry.

5

The method of aiding an individual's sleep typically indicates aiding in the sense of providing any one or more of the above mentioned benefits.

10 Typically, the percentage of individuals who, after taking a dose of triprolidine before sleeptime, wake refreshed after sleeping is in the range 1-100%, more typically, 5-70%, most typically 10-35%. An especially typical range as aforesaid is 15-30% or even more especially 20-30%.
15 Typically, by the terms "waking refreshed" or "wake refreshed" is meant that an individual felt at least refreshed on waking, preferably, the terms are defined as the individual felt very refreshed or refreshed in accordance with the Loughborough sleep log.

20

Typically, the percentage of individuals who, after taking a dose of triprolidine before sleeptime, wake refreshed after sleeping is more than 2%, more typically, more than 8% and most typically, more than 15%. An especially
25 typical level as aforesaid is more than 18% or even more especially more than 20%.

By the term sleeping as referred to herein is meant an individual in at least Stage I sleep. By the term
30 sleeptime as referred to herein is meant the time an individual desires to go to sleep.

Typically, the percentage of individuals who, after taking a dose of triprolidine before sleeptime, felt alert after
35 sleeping is in the range 1-100%, more typically, 5-60%, most typically 10-30%. An especially typical range as aforesaid is 15-30% or even more especially 20-30%.

Typically, the percentage of individuals who, after taking a dose of triprolidine before sleeptime, felt alert after sleeping is more than 2%, more typically, more than 8%,
5 most typically more than 12%. An especially typical level as aforesaid is more than 16%.

By the term felt alert is meant that an individual felt at least alert on waking. Preferably, the term is defined as
10 the individual felt alert, very alert or extremely alert in accordance with the Karolinska 9-point scale.

Typically, the percentage of individuals who, after taking a dose of triprolidine before sleeptime, felt sleepy on
15 waking is less than 25%, more typically, less than 20%, most typically less than 15%. An especially typical level as aforesaid is less than 14% or even more especially a mean level of less than 12%.

20 By the term felt sleepy is meant that an individual felt sleepy on waking. Preferably, the term is defined as the individual felt sleepy or very sleepy in accordance with points 8 or 9 of the Karolinska 9-point scale.

25 Preferably, in use of the present invention as defined herein, the mean subjective feeling of refreshedness after waking as, for instance, determined on a 5 point scale, e.g.. by the morning log of the Loughborough sleep log, is increased by at least 2%, more typically, by at least 4%,
30 most typically, by at least 5%, as compared with an equivalent dose of placebo.

Typically, in use of the present invention as defined herein, the mean subjective feeling of refreshedness after
35 waking as for instance, determined on a 5 point scale, e.g.. by the morning log of the Loughborough sleep log, is increased by between 1-20%, more typically, 1-15%, most

typically 2-10% as compared with an equivalent dose of placebo.

The degree of refreshedness and quality of sleep may be
5 determined by the "morning" log of the Loughborough
sleep log with the highest degree of refreshedness or
quality of sleep being represented as 1 and the lowest
being represented as 5. Accordingly, the percentage
increase in refreshedness or quality of sleep is measured
10 in this context by the decrease in the mean refreshedness
or quality of sleep.

Preferably, by the use of the present invention, the
response of awakening very refreshed or refreshed, as
15 determined, for instance, by the morning log of the
Loughborough sleep log, is improved by at least 20 %, more
preferably, by at least, 30%, most preferably by at least
40%, as compared with an equivalent dose of placebo.

20 Typically, by the use of the present invention, the
response of awakening very refreshed or refreshed, as
determined, for instance, in accordance with the morning
log of the Loughborough sleep log is improved by between
5% and 100%, more typically, by between 10% and 80%, most
25 typically by between 20% and 60%, especially 40-55% and
more especially 40-45% as compared with an equivalent dose
of placebo.

Preferably, by the use of the present invention, the
30 response of feeling extremely alert, very alert or alert ,
as determined, for instance, in accordance with the
Karolinska 9-point scale, is improved by at least 2%, more
preferably, by at least, 5%, most preferably by at least
10%, as compared with an equivalent dose of placebo.

35 Typically, by the use of the present invention, the
response of feeling extremely alert, very alert or alert,

as determined, for instance, in accordance with the Karolinska 9 point scale, is improved by between 1% and 40%, more typically, by between 2% and 30%, most typically by between 10% and 20%, as compared with an equivalent
5 dose of placebo. An especially preferred range is 10-30%.

Preferably, by the use of the present invention, the response of feeling sleepy and needing to make some effort to stay awake or very sleepy, as determined, for instance,
10 in accordance with points 8 and 9 of the Karolinska 9 point scale, is improved (i.e. decreased) by at least 2%, more preferably, by at least, 4%, most preferably, by at least 10%, as compared with an equivalent dose of placebo.

15 Typically, by the use of the present invention, the response of feeling sleepy and needing to make some effort to stay awake or very sleepy, as determined, for instance, in accordance with points 8 and 9 of the Karolinska 9 point scale is improved (i.e. decreased) by between 1% and
20 100%, more typically, by between 2% and 75%, most typically, by between 4% and 60%, as compared with an equivalent dose of placebo.

Preferably, in use of the present invention as defined
25 herein, the sleeptime awakenings, as for example determined by the Night diary of the Loughborough sleep log, may be decreased by 2-40%, typically, by 10-35%, most typically by 15-30%, as compared with an equivalent dose of placebo. An especially preferred range is 15-40%.

30 Preferably, in use of the present invention as defined herein, the sleeptime awakenings may be decreased by more than 5%, more preferably by more than 10%, most preferably, by more than 15%, as compared with an equivalent dose of placebo.

35

Preferably, in use of the present invention as defined herein, sleep disturbance index (SDI), as for instance

determined by actimetry, may be decreased by more than 5%, more preferably by more than 10%, most preferably by more than 15% as compared with an equivalent dose of placebo.

- 5 Preferably, in use of the present invention as defined herein, SDI may be decreased by 5-30%, more typically 5-25%, most typically 10-20 % as compared with an equivalent dose of placebo. An especially preferred range is 10-30%, more especially 10-25%.

10

- Preferably, in use of the present invention as defined herein, time to sleep onset (TTSO) as, for instance, determined by actimetry may be decreased by 5-40%, more typically 15-35%, most typically 20-30% as compared with
15 an equivalent dose of placebo. An especially preferred range is 20-40%, more especially 20-35%.

- Preferably, in use of the present invention as defined herein, the time to sleep onset (TTSO) as compared with an
20 equivalent dose of placebo is decreased by at least 10%, more preferably by at least 15%, most preferably, by at least 20%.

- Preferably, the quality of sleep experienced as felt after
25 awakening is also improved by the use of the present invention, typically the quality of sleep is improved by 2-30%, more typically 5-30%, most typically 10-20% as compared with an equivalent dose of placebo and as, for instance, determined by the morning log of the
30 Loughborough sleep log. Typically, in use of the present invention as defined herein, the quality of sleep is improved by at least 2%, more preferably at least 5%, most preferably at least 10% as compared with an equivalent dose of placebo.

35

- Preferably, in use of the present invention, the time to fall asleep as determined, for instance, by the Night

diary of the Loughborough sleep log is decreased by 1-40%, more typically 5-35%, most typically 10-30%. An especially preferred range is 10-40%, more especially 10-35%. Typically, in use of the present invention as
5 defined here, the time to fall asleep as aforementioned is decreased by at least 2%, more typically, by at least 5%, most typically by at least 10% as compared with an equivalent dose of placebo.

10 Preferably, by the use of the present invention, the response of sleeping extremely well or very well, as determined, for instance, in accordance with the morning log of the Loughborough sleep log, is improved by at least 20%, more preferably, at least, 35%, most preferably at
15 least 50%, as compared with an equivalent dose of placebo.

Preferably, by the use of the present invention, the response of sleeping extremely well or very well, as determined, for instance, in accordance with the morning
20 log of the Loughborough sleep log, is found for at least 20% of individuals, more preferably, at least 25%, most preferably, at least 30%. For example over 35% of individuals had such a response.

25 Typically, by the use of the present invention, the response of sleeping extremely well or very well, as determined, for instance, in accordance with the morning log of the Loughborough sleep log is improved by between 10% and 200%, most typically, by between 20% and 150%,
30 more typically by between 25% and 135% as compared with an equivalent dose of placebo. Typically, by the use of the present invention, the response of sleeping extremely well or very well, as determined, for instance, in accordance with the morning log of the Loughborough sleep log is
35 found for between 25% and 100% of individuals, more typically, 30-80% most typically 35-70%. Especially

preferred is the response in at least between 35-60%, of individuals, more especially 35-45%.

It will be understood that references herein to
5 "triprolidine" include the compound (E)-2-[1-(4-methylphenyl-3-(1-pyrrolidinyl)-1-propenyl]pyridine as well as salts thereof that are acceptable for administration to the human body. Acid addition salts may particularly be mentioned, including the hydrobromide and
10 hydrochloride salts. The hydrochloride salt, i.e. triprolidine hydrochloride, is particularly preferred for use in accordance with the invention. Solvates of triprolidine, notably hydrates, e.g. monohydrates, and to the extent that triprolidine may exist in polymorphic
15 forms, all such polymorphs are within the scope of the invention.

The term "refreshed" as used herein means an individual waking refreshed or alert after a dose of triprolidine has
20 been administered prior to sleep. In this context, the determination of whether an individual is feeling "refreshed" may be made by a subjective test. An example subjective test is measuring the degree of alertness on, for instance, the Karolinska scale or the feeling of being
25 refreshed as determined by, for instance, the Loughborough sleep log. Alternatively, refreshedness may be based upon the inverse relationship between refreshedness and relative levels of sleepiness as determined by the Karolinska scale.

30

By the term individual as referred to herein is meant any mammal or human.

The administration of the active ingredient in accordance
35 with the invention may be beneficial in that there is evidence that users feel more refreshed upon awakening, which is not the case with other treatments for sleep

disorders, or indeed in the absence of any treatment, and do not experience grogginess or a "hangover" effect after the required number of hours sleep. This too is surprising in view of the fact that such feelings have
5 been reported in relation to other active ingredients which have a comparable mode of action to that of triprolidine. Furthermore, there is no evidence that repeated use of the active ingredient over the course of several days leads to any loss of effect.

10

The administration of the active ingredient in accordance with the invention may also be beneficial in that it may decrease the time required for a user to fall asleep, which is surprising in view of the previously-reported
15 studies on volunteers. In addition, the total period of sleep may be increased and the incidence and duration of night-time awakenings experienced by the user may be reduced.

20 The active ingredients are preferably formulated in such a manner as to lead to non-sustained, substantially immediate release of the active ingredient, i.e. the formulation is preferably free of ingredients intended or effective to prolong or sustain release of the active
25 ingredient.

Administration of the active ingredient in accordance with the invention may be by a variety of routes. However, most commonly the active ingredient will be administered
30 orally. An alternative mode of administration may be administration to the mucous membranes of the nasal passages. Further modes of administration are transdermal (e.g. using transdermal patches or bandages), rectal (e.g. as suppositories), optical, sub-lingual, buccal and
35 pulmonary.

For oral administration, the active ingredient may be put up in a variety of dosage forms. Most commonly, the active ingredient will be formulated and administered as a tablet or the like. However, formulation as capsules, 5 lozenges, drinks or as a syrup (solution or suspension) may also be possible, as may other dosage forms such as a consumable film for instance a buccal wafer or oral sprays.

10 For nasal administration, the active ingredient may be formulated as a solution, emulsion or suspension and administered by means of a spray using a suitable delivery device. Alternatively, for pulmonary administration, the active ingredient may be administered as a powder, either 15 from a pressurised aerosol delivery device or from a so-called dry powder inhaler.

For formulation in the presently preferred form, i.e. as a tablet, the active ingredient will generally be combined 20 with various excipients in a manner which is known per se. In particular, the tablet will generally comprise one or more diluents or bulking agents. A diluent may also serve as a disintegrant, or the formulation may incorporate a separate disintegrant. A lubricant may also be included 25 to facilitate release of the formed tablets from the tableting dies of a tablet forming machine.

Thus, according to a further aspect of the invention, there is provided a tablet for enabling an individual to 30 wake refreshed after sleeping, which tablet comprises triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent as active ingredient in admixture with one or more diluents and/or a disintegrant, the tablet comprising more than 35 0.01mg and less than 4.9mg triprolidine.

As noted above, the formulation may incorporate one diluent or bulking agent, or more than one. Formulations are preferred which contain blends of two or more diluents, one of which may also serve as a disintegrant.

5

Preferred materials for the diluent or bulking agents include polysaccharides and derivatives thereof, and saccharides.

10 Polysaccharides which may be used include starch, e.g. maize starch, cellulose, e.g. powdered cellulose and microcrystalline cellulose, water-insoluble modified starches, e.g. sodium carboxymethyl starch, water-insoluble cellulose derivatives, e.g. croscarmellose
15 sodium (cross-linked sodium carboxymethyl cellulose), cross-linked polyvinylpyrrolidone and alginic acid.

Another preferred form of diluent is a saccharide. Suitable saccharides include, for example, sucrose,
20 lactose, dextrose, sorbitol, mannitol, xylitol and maltodextrin. Lactose and sucrose are preferred saccharides. Lactose is especially preferred. Saccharide diluents may also be beneficial in terms of modifying the taste of the formulation.

25

Particularly preferred diluents are dicalcium phosphate, microcrystalline cellulose, e.g. the products sold as Avicel PH-101 and Avicel PH-102 (Avicel is a Trade Mark) by the FMC Corporation of Philadelphia, Pa., USA, and
30 lactose.

Another preferred disintegrant is a croscarmellose sodium, for example the product sold as Ac-Di-Sol (Ac-Di-Sol is a Trade Mark) by the FMC Corporation. This product, when
35 included in the formulation, also serves as a disintegrant.

The disintegrant has the effect of causing the tablet composition to disintegrate under the conditions found in the gastro-intestinal tract. Apart from croscarmellose sodium, examples of disintegrants include one or more of
5 wheat starch, maize starch, potato starch, sodium starch glycolate, low-substituted hydroxypropyl cellulose, alginic acid, cross-linked polyvinylpyrrolidone and magnesium aluminium silicate. Preferred disintegrants are those which swell on the action of water thus causing the
10 ingredients in the tablet to be pushed apart and out into the aqueous disintegration medium. The preferred disintegrant is croscarmellose sodium. The disintegrant is present at an effective disintegrating amount, for example up to 25% by weight of the composition, more
15 preferably 1-25% w/w, further preferably 3-20% w/w and most preferably 5-15% by weight of the composition.

Particularly preferred compositions, in a particular tablet compositions, include a blend of a cellulosic
20 diluent, a saccharide diluent and a disintegrant. The preferred cellulosic diluent is microcrystalline cellulose, the preferred saccharide is lactose and the preferred disintegrant is croscarmellose sodium.

25 A preferred formulation, in particular a tablet formulation, comprises the cellulosic diluent, the saccharide diluent and the disintegrant in the ratio of 0.01-10 parts by weight of cellulosic diluent, 0.01-10 parts by weight of saccharide diluent to 1 part by weight
30 of disintegrant. More preferably, the formulation contains 2-5 parts by weight of cellulosic diluent per part by weight of disintegrant, and 4 to 7 parts by weight of saccharide diluent per part by weight of disintegrant.

35 The diluents and/or disintegrant are preferably incorporated into the compositions in finely divided (powder) form.

The diluents and disintegrant preferably together constitute in excess of 80% w/w of the tablet formulation, more preferably in excess of 90% w/w, and most preferably
5 in excess of 94% w/w.

The lubricant may be, for example, stearic acid, a metallic stearate, a polyethylene glycol of molecular weight of 4,000 or more, or purified talc. The preferred
10 lubricant is a metallic stearate, particularly magnesium stearate, which may be present in the formulation at relatively low levels, typically less than 1% or 0.5% by weight.

15 It has been found to be particularly advantageous for the tablet formulation to be formed with a coating, preferably a sugar coating or film coating process, more preferably a film coating comprising a hydrophilic polymer, particularly a cellulose derivative such as a methylated
20 cellulose derivative, e.g. hydroxyethylmethylcellulose and, particularly, hydroxypropylmethylcellulose.

The coating may also comprise an inorganic filler material, most preferably French chalk, to enhance the
25 physical properties of the coating and prevent cracking etc, and also a pigment, e.g. a titanium dioxide pigment dispersion.

It has been found that, in addition to improving the
30 appearance of the tablet and acting as a barrier to ingress of moisture, the film coating is also effective in masking the taste of the active ingredient.

Administration of the active ingredient in accordance with
35 the invention may be by means of a consumable film. The films may be edible and upon disintegration, the triprolidine and other active may be absorbed via the

buccal cavity or the digestive tract. Preferably, the triprolidine and other active are formulated to be absorbed via the digestive tract. Suitable formulations are disclosed in WO 00/18365, the content of which insofar
5 as it relates to consumable film formulations which may incorporate triprolidine hydrochloride or methods of producing such formulations is incorporated herein by reference.

- 10 For consumable film formulation in the presently preferred form, the active ingredient will generally be combined with various excipients in a manner which is known per se.

Suitable excipients for consumable films are disclosed in
15 WO 00/18365 and these are incorporated herein by reference.

Thus, according to a further aspect of the invention, there is provided a consumable film for enabling an
20 individual to wake refreshed after sleeping, which film comprises triprolidine as active ingredient in combination with at least one further active pharmaceutical agent in admixture with one or more suitable excipients, the film comprising more than 0.01mg and less than 4.9mg
25 triprolidine. The film is preferably, substantially free from menthol, thymol, methyl salicylate and eucalyptol.

The consumable film is one adapted to adhere and dissolve in a mouth of a consumer and comprises at least one water
30 soluble polymer. Preferably, the said water soluble polymer is selected from the group consisting of pellulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone,

carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.

10

Preferably, other film excipients may be utilised and these may be selected from water, antimicrobial agents, additional film-forming agents, plasticizing agents, flavouring agents, sulphur precipitating agents, saliva stimulating agents, buffering agents, cooling agents, surfactants, stabilising agents, emulsifying agents, thickening agents, binding agents, colouring agents, sweeteners, fragrances and the like.

Saliva stimulating agents can also be added as film excipients. Saliva stimulating agents include food acids such as citric, lactic, malic, succinic, ascorbic, adipic, fumaric and tartaric acids. Preferred food acids are citric, malic and ascorbic acids. The amount of saliva stimulating agents in the film is from about 0.01 to about 12 wt%, preferably about 1 wt% to about 10 wt%, even more preferably about 2.5 wt% to about 6 wt%.

Buffering agents include salts of the aforementioned acids such as alkali metal salts of the food acids detailed above. An especially preferred buffering agent is sodium citrate. The amount of buffering agent may be in accordance with that suitable to complement the saliva

stimulating agent as detailed above but is typically 0.01 - 12 wt%.

Preferred plasticizing agents for the films include
5 triacetin in amounts ranging from about 0 to about 20wt%, preferably about 0 to 2 wt%. Other suitable plasticizing agents include monoacetin and diacetin.

Preferred cooling agents for the films include monomethyl
10 succinate, in amounts ranging from about 0.001 to 2.0 wt%, preferably about 0.2 to about 0.4 wt%. A monomethyl succinate containing cooling agent is available from Mane. Inc. Other suitable cooling agents include WS3, WS23, Ultracool II and the like.

15 Preferred surfactants for the films include mono and diglycerides of fatty acids and polyoxyethylene sorbitol esters, such as, Atmos 300 and Polysorbate 80. The surfactant can be added in amounts ranging from about 0.5
20 to about 15 wt %, preferably about 1 to about 5 wt% of the film. Other suitable surfactants include pluronic acid, sodium lacryl sulphate, and the like.

Preferred stabilising agents for the films include xanthan
25 gum, locust bean gum and carrageenan, in amounts ranging from about 0 to about 10wt%, preferably about 0.1 to about 2wt% of the film. Other suitable stabilising agents include guar gum and the like.

30 Preferred emulsifying agents for the films include triethanolamine stearate, quaternary ammonium compounds, acacia, gelatin, lecithin, bentonite, veegum and the like,

in amounts ranging from about 0 to about 3wt%, preferably about 0.01 to about 07 wt% of the film.

Preferred thickening agents for the films include
5 methylcellulose, carboxyl methylcellulose, and the like, in amounts ranging from about 0 to about 20wt%, preferably about 0.01 to about 5 wt%.

Preferred binding agents for the films include starch, in
10 amounts ranging from about 0 to about 10wt%, preferably about 0.01 to about 2 wt% of the film.

Suitable sweeteners for the films that can be included are those well known in the art and similarly, flavourings and
15 colourings that can be included are those known in the art. A suitable definition of sweeteners, flavourings and colourings is found in WO 00/18365, page 12 line 17 - page 16 line 19, the contents of which are hereby incorporated herein by reference.

20 The tablet formulation may be prepared by a process involving dry blending or wet or dry granulation. However, it is preferred to use a manufacturing method which involves direct compression into a tablet without an
25 intermediate, e.g. a wet or dry granulation, stage.

The formulation may be made by dry mixing the active ingredient with the other ingredients, e.g. the lubricant and diluents and disintegrant, e.g. in a powder blending
30 machine. It is particularly preferred that the active ingredients are dispersed by progressive dilution with agitation in a proportion, e.g. about one-half, of the excipients so as to achieve even distribution of the active ingredient in the excipients, and then to add the
35 remainder of the excipients with further agitation and

mixing. The mixture may then be compressed in a tablet forming machine and a coating, preferably a sugar coat or a film coat may then be applied to the tablets so formed by spraying the tablets with a solution or suspension of
5 the coating-forming ingredients while the tablets are tumbled.

Such a direct tablet compression manufacturing method has been found to be beneficial in that it avoids problems
10 attributable to crystal growth and changes in morphology which might occur in a wet granulation process.

Other, currently less preferred, dosage forms may be prepared in a manner which is generally known per se. For
15 example, syrups may be prepared by dissolving or suspending the active ingredient in a liquid vehicle, e.g. water, optionally with suspending agents or the like, e.g. cellulose derivatives, gums etc.

20 For administration by inhalation, via nose or mouth, the formulations may be formulated with a compressed gas or liquified gas propellant, e.g. any conventionally used propellant such as a chlorofluorocarbon, hydrofluorocarbon, compressed hydrocarbon, nitrogen etc.
25 Alternatively, the active ingredient may be formulated as a dry powder, generally in admixture with a diluent such as crystalline lactose.

The amount of active ingredient to be administered in a
30 single dose may vary quite widely, depending inter alia on the desired effect and the mode of administration. However, a formulation for oral administration, e.g. a tablet, will generally contain at least 0.01 and up to 20mg of active ingredient, more commonly at least 0.5mg
35 and less than 10mg of active ingredient, most commonly no more than 5mg, e.g. 1.25 or 2.5mg. Doses of formulations for administration by nasal and sub-lingual

administration, which would be expected to deliver the active ingredient more quickly and efficiently, may contain less active ingredient, e.g. between 0.1 and 1.0mg, e.g. about 0.5mg and generally at a level of 20% of the oral dose levels mentioned herein. Preferably, such nasal and sub-lingual formulations contain active ingredient in the range 0.01-2.5mg, more preferably, 0.05-1.0mg and most preferably, 0.1-0.5mg.

10 In general, the desired dose (which may comprise one or more unit doses, e.g. one or two tablets or the like) will be taken by a user prior to the desired time at which it is desired for the composition to take effect. Most commonly, the dose will be taken at night-time, i.e. prior to the user sleeping through hours of darkness. Typically, the dose may thus be taken after 8pm in the evening or later, say after 9pm or after 10pm. Typically, it may be recommended that the user take the composition between 0 , more commonly 1 minute and 2 hours prior to the time at which he or she wishes to fall asleep. Most commonly, the composition may be taken about 10 to 30 minutes prior to that time. In addition, however, the active ingredient may be effective, particularly at lower doses, in restoring sleep, e.g. in the event of night-time waking.

Preferably, the use of triprolidine in any aspect of the invention as defined herein is its use as active ingredient. Preferably, the triprolidine in any aspect of the invention defined herein is in the form of a non-toxic effective dose, preferably, suitable for any given mammal or human and determined in accordance with age and weight.

Preferably, to obtain the benefits on waking or otherwise as defined herein, the active ingredient of triprolidine administered before sleeptime is less than 10mg, typically less than 5mg, more preferably, less than 4.5mg, most

preferably less than 4.0mg. Especially preferred is a dose as aforesaid of less than 3.5mg and most especially preferred is a dose of less than 3.0mg. Typically, the dose of triprolidine is between 0.01 and 10.0mg, preferably, between 0.01 and 4.9mg, more preferably, between 0.1 and 4.5mg, most preferably between 0.5 and 4mg. Especially preferred is a dose of between 1 and 3.5mg and more especially a dose of between 2.0 and 3.0mg. Most especially preferred is a dose as aforesaid of about 2.5mg or 1.25mg. Preferably, the above dosage levels are based on triprolidine hydrochloride monohydrate and amounts of other salts or hydrates should be varied accordingly to deliver the equivalent amount of active ingredient.

In the formulations of the present invention, the triprolidine may be in any suitable release form such as a slow release, sustained release, immediate release or uncontrolled release form. The formulation may also be in any one or more of the following delivery forms:-

Pastilles
lozenge
chewable tablets
fondant-fill tablets
coated or uncoated tablets
sub-lingual tablets
fast-melt tablets
hot or cold drinks
syrups
drops
emulsions
dry powder
suspension
transdermal patch
suppository
consumable films such as buccal wafers

sub-lingual and nasal sprays

Preferably, the dose of the triprolidine and further active agent in accordance with the invention may be taken
5 by an individual before it is desired to go to sleep (sleeptime), preferably less than two hours before sleeptime, more preferably, less than one hour before sleeptime, most preferably, less than 20 minutes before sleeptime. Especially preferred is to take the dose of
10 triprolidine and further active agent less than 15 minutes before sleeptime.

Preferably, the dose of triprolidine and further active agent is less than 4 doses per day (24 hour period), more
15 preferably, less than 3 doses per day, most preferably less than 2 doses per day. Especially, preferred is 1 dose per day.

The packaging of the invention as defined herein may be in
20 any suitable form such as, for example, a blister pack, bottle, tamper-proof container, sachet, box, etc. The packaging of the invention may be associated with instructions for any of the features or preferred features of the invention as defined herein.

25 For the avoidance of doubt, reference to the "use of the present invention" herein should be taken to include "the method of the invention", and "use of a pharmaceutical formulation" as well as use of the present
30 invention per se.

Advantageously, the use of triprolidine and further active agent in the present invention results in a reduced hangover or morning grogginess effect as compared with
35 other sleep aids or sleep disorder remedies. More advantageously, the use of triprolidine and further active agent in the present invention provides an improved degree

of refreshedness or more refreshed feeling upon waking as determined by the Loughborough sleep log, Leeds sleep evaluation questionnaire or Karolinska scale and as compared with placebo.

5

For the avoidance of doubt, reference to quantities of triprolidine herein should be taken as references to quantities of the hydrochloride mono hydrate (HCl. H₂O) form. However, it should be appreciated that the
10 invention extends to other forms, including all pharmaceutically active salts and hydrates thereof.

The term refreshed as used herein may be substituted by any term selected from alert, invigorated, revitalised,
15 re-energised, recharged, rejuvenated, attentive, awake or words having the like effect or equivalent general meaning and the term refreshedness may also be substituted by the grammatical equivalent thereof from the words aforesaid. In addition, the term alert as used herein can be
20 substituted by any of the above alternative terms.

Non limiting embodiments of the invention will now be illustrated with reference to the accompanying examples.

25

Experimental

The dosage forms were prepared as tablets, lozenges and syrups as follows.

30

Tablet Manufacture

Sieve the lactose, pregelatised maize starch, maize starch, ac-di-sol and active materials into a granulator
35 mixer and mix for 5 minutes. In a side vessel prepare the granulating solution using plasdone and water. Add this solution to the granulator, until a suitable granule is

formed. Dry the granule in a fluid bed dryer and sieve. Sieve the magnesium stearate through a 30 mesh sieve and add to the granule and blend for 2 minutes. Compress the blend to the appropriate tablet weight.

5

Lozenge Manufacture

Sieve the calcium carbonate and active materials through a 30 mesh sieve into a granulator mixer. Mix for 5 minutes.

- 10 In a side vessel prepare the granulating solution using plasdone and water. Add this solution to the granulator, until a suitable granule is formed.

- 15 Dry the granule in a fluid bed dryer and sieve. Sieve the aerosil and magnesium stearate through a 30 mesh sieve and add to the granule and blend for 2 minutes.

- 20 The base solution (sugar and glucose) is pumped into the pre-cooker and heated to $114^{\circ}\text{C} \pm 5^{\circ}\text{C}$ to increase the solids content from approximately 72% solids to approximately 85% solids. The heated mass is then pumped to the main cooker and further heated to $140^{\circ}\text{C} \pm 5^{\circ}\text{C}$ to achieve a solids content of approximately 96% solids. A vacuum of 0.8 ± 0.1 of a bar is then applied to achieve
- 25 a mass having a solids content of approximately 98%. The hot mass is discharged continuously into a mixing chamber. Flavour and the active granule are dosed into the cooked mass at a rate to meet the finished product composition, given the flow rate of the cooked mass. The mixed mass is
- 30 continuously discharged from the mixing chamber, passed down a tempering belt, cooled and collected in the batch former. The mass is drawn into a rope and passed through a drop former. Lozenge weight checks are made at regular intervals. The lozenges pass through a cooling conveyor
- 35 which operates within the temperature range of $12 - 25^{\circ}\text{C}$ before being collected into storage containers.

Syrup manufacture

In a suitable stainless steel manufacturing vessel the
5 hydroxyethylcellulose is dispersed in 2300 litres of
liquid sucrose.

The mixture is then homogenised until smooth and lump
free. The remaining 700 litres of liquid sucrose is then
10 added to the bulk along with 500 litres of purified water
and mixed until homogenous. The mixture is then left to
stand for 2 hours to allow the hydroxyethylcellulose to
hydrate.

15 In a suitable stainless steel manufacturing vessel the
glycerol is warmed to 55-60°C and the active materials
added and mixed until dissolved. This is then added to the
hydroxyethylcellulose/liquid sucrose bulk mixture with
stirring. The glycerin vessel is then rinsed with 100
20 litres of purified water that is also added to the bulk
vessel. The mixture is then stirred until homogenous.

The citric acid, sodium citrate and sodium saccharin are
then added directly to the bulk solution and stirred until
25 dissolved. The colouring ingredients are dissolved in 10
litres of purified water in a suitable stainless steel
vessel before being added to the bulk solution with
mixing. The vessel is rinsed with 10 litres of purified
water that is also added to the bulk mixture with
30 stirring.

The levomenthol, domiphen bromide and flavours are mixed
in 80 litres of ethanol 96% in a suitable stainless steel
vessel. The solution is added, with stirring to the bulk
35 mixture that has been pre-cooled to below 32°C. The
flavouring manufacturing vessel is then rinsed with 20

litres of ethanol 96% that is then also added to the bulk mixture with stirring.

Final bulk production

5

The bulk mixture is made up to final volume with purified water and stirred for 30 minutes to ensure homogeneity. An in-process viscosity check is performed at this point.

10

Examples of tablet formulations which may be used in the invention are as follows:

Examples

Pain

Tablet Formulae (mg/tab)

		Tripolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29- 32	Tablet wt (mg)
Ibuprofen	200	2.5	95.5	12	48	25	2	15	400
	400	2.5	95.5	12	48	25	2	15	600
Ibuprofen									
Flurbiprofen	50	2.5	145.5	12	48	25	2	15	300
Dexketoprofen	12.5	2.5	183	12	48	25	2	15	300
Diclofenac Sodium	75	2.5	145.5	12	48	25	2	15	325
Celecoxib	200	2.5	95.5	12	48	25	2	15	400
Indomethacin	50	2.5	145.5	12	48	25	2	15	300
Ketoprofen	100	2.5	145.5	12	48	25	2	15	350
Mefenamic acid	500	2.5	148	12	48	25	2	15	750
Naproxen	250	2.5	95.5	12	48	25	2	15	450
Rofecoxib	12.5	2.5	183	12	48	25	2	15	300
Piroxicam	20	2.5	175.5	12	48	25	2	15	300

Tenoxicam	20	2.5		175.5	12	48	25	2	15	300
Aspirin	500	2.5		148	12	48	25	2	15	750
Paracetamol	500	2.5		148	12	48	25	2	15	750

Lozenge Formulae (mg/loz)

		Triprolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	Lozenge wt (mg)
Ibuprofen	200	2.5	0.05	0.249	150	700	1241	7.05	47	1.5	2350
Ibuprofen	400	2.5	0.05	0.249	150	600	1141	7.05	47	1.5	2350
Flurbiprofen	8.75	2.5	0.05	0.249	7.5	1010	1266	7.05	47	1.5	2350
Dexketoprofen	12.5	2.5	0.05	0.249	10	1010	1196	7.05	47	1.5	2350
Diclofenac Sodium	75	2.5	0.05	0.249	70	800	1390	7.05	47	1.5	2350
Celecoxib	200	2.5	0.05	0.249	150	700	1241	7.05	47	1.5	2350
Indomethacin	50	2.5	0.05	0.249	50	850	1342	7.05	47	1.5	2350
Ketoprofen	100	2.5	0.05	0.249	75	825	1292	7.05	47	1.5	2350
Mefenamic acid	500	2.5	0.05	0.249	150	500	1142	7.05	47	1.5	2350
Naproxen	250	2.5	0.05	0.249	7.5	680	1354	7.05	47	1.5	2350
Rofecoxib	12.5	2.5	0.05	0.249	7.5	1010	1196	7.05	47	1.5	2350
Piroxicam	20	2.5	0.05	0.249	15	950	1307	7.05	47	1.5	2350
Tenoxicam	20	2.5	0.05	0.249	15	950	1307	7.05	47	1.5	2350
Aspirin	500	2.5	0.05	0.249	150	500	1142	7.05	47	1.5	2350
Paracetamol	500	2.5	0.05	0.249	150	500	1142	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Tripolidi ne HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxyethyl cellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromi de	Colour	Water
Ibuprofen	200	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Ibuprofen	400	2.5	0.8	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Flurbiprofen	8.75	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Dexketoprofen	12.5	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Diclofenac Sodium	75	2.5	0.95	2.95	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Celecoxib	200	2.5	0.9	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Indomethacin	50	2.5	0.95	2.95	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Ketoprofen	100	2.5	0.95	2.95	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Mefenamic acid	500	2.5	0.75	2.75	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Naproxen	250	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Rofecoxib	12.5	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Piroxicam	20	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Tenoxicam	20	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Aspirin	500	2.5	0.75	2.75	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Paracetamol	500	2.5	0.75	2.75	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml

Triptans

Tablet Formulae (mg/tab)

		Tripolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29- 32	<i>Tablet wt. (mg)</i>
Sumatriptan	50	2.5	145.5	12	48	25	2	15	300
Zolmitriptan	2.5	2.5	193	12	48	25	2	15	300

Lozenge Formulae (mg/loz)

		Tripolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	<i>Lozenge wt (mg)</i>
Sumatriptan	50	2.5	0.05	0.249	50	850	1342	7.05	47	1.5	2350
Zolmitriptan	2.5	2.5	0.05	0.249	10	1020	1196	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Triprolidine HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxyethylcellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromide	Colour	Water
Sumatriptan	50	2.5	0.95	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25		
Zolmitriptan	2.5	2.5	0.8	3.0	12.5	17	50	12.5	0.009	0.1	1	0.25		

Antivirals

Tablet Formulae (mg/tab)

		Triprolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29-32	Tablet wt (mg)
Amantadine	100	2.5	195.5	12	48	25	2	15	400
Aciclovir	200	2.5	95.5	12	48	25	2	15	400
Famciclovir	250	2.5	95.5	12	48	25	2	15	450

Lozenge Formulae (mg/loz)

		Tripolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	Lozenge wt (mg)
Amantadine	100	2.5	0.05	0.249	150	800	1341	7.05	47	1.5	2350
Aciclovir	200	2.5	0.05	0.249	150	700	1241	7.05	47	1.5	2350
Famciclovir	250	2.5	0.05	0.249	150	650	1191	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Tripolidine HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxye thylcellul ose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromi de	Col our	Water
Amantadine	100	2.5	0.9	3.0	12.5	17	50	12.5	0.009	0.1	1	0.25		
Aciclovir	200	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25		
Famciclovir	250	2.5	0.9	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25		

Allergy

Tablet Formulae (mg/tab)

		Triprolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29- 32	Tablet wt (mg)
Acrivastine	8	2.5	187.5	12	48	25	2	15	300
	10	2.5	185.5	12	48	25	2	15	300
Cetirizine	10	2.5	185.5	12	48	25	2	15	300
	120	2.5	75.5	12	48	25	2	15	300
Terfenadine	60	2.5	145.5	12	48	25	2	15	300
Betamethasone	5	2.5	190.5	12	48	25	2	15	300
Clemastine	1	2.5	194.5	12	48	25	2	15	300
Bropheniramine	8	2.5	187.5	12	48	25	2	15	300
Chlorpheniramine	4	2.5	191.5	12	48	25	2	15	300

Lozenge Formulae (mg/loz)

		Triprolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol content s)	Flavour	Water (ml)	Plasdone K29-32	Lozeng e wt (mg)

Acrivastine	8	2.5	0.05	0.249	10	1010	1264	7.05	47	1.5	2350
Cetirizine	10	2.5	0.05	0.249	10	1010	1262	7.05	47	1.5	2350
Loratadine	10	2.5	0.05	0.249	10	1010	1262	7.05	47	1.5	2350
Fexofenadine	120	2.5	0.05	0.249	100	900	1172	7.05	47	1.5	2350
Terfenadine	60	2.5	0.05	0.249	50	1000	1182	7.05	47	1.5	2350
Betamethasone	5	2.5	0.05	0.249	10	1010	1267	7.05	47	1.5	2350
Clemastine	1	2.5	0.05	0.249	10	1010	1273	7.05	47	1.5	2350
Bropheniramine	8	2.5	0.05	0.249	10	1010	1264	7.05	47	1.5	2350
Chlorpheniramine	4	2.5	0.05	0.249	10	1010	1260	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

	Triprolidine HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxyethylcellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromide	Colour	Water
Acrivastine	8	2.5	0.9	2.9	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Cetirizine	10	2.5	0.8	2.8	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Loratadine	10	2.5	0.99	2.99	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Fexofenadine	120	2.5	0.99	2.99	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Terfenadine	60	2.5	0.95	2.95	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Beclamethasone	5	2.5	0.9	2.8	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Clemastine	1	2.5	0.95	2.95	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Bropheniramine	8	2.5	0.95	2.95	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml
Chlorpheniramine	4	2.5	0.95	2.95	12.5	17	50	0.009	0.1	1	0.25	0.9	to 5ml

Cough/Cold

Tablet formulae (mg/tab)

		Tripolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29- 32	Tablet wt (mg)
Ambroxol	30	2.5	165.5	12	48	25	2	15	300
Guaiphenesin	100	2.5	195.5	12	48	25	2	15	400
Dextromethorphan	10	2.5	185.5	12	48	25	2	15	300
Menthol	10	2.5	185.5	12	48	25	2	15	300
Phenylpropanolamine	12.5	2.5	183	12	48	25	2	15	300

Lozenge Formulae (mg/loz)

		Tripolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	Lozenge wt (mg)
--	--	--------------------	---------	-----------------------	----------------------	----------------------------------	-----------------------------------	---------	---------------	--------------------	--------------------

Ambroxol	30	2.5	0.05	0.249	10	1000	1262	7.05	47	1.5	2350
Guaiphenesin	100	2.5	0.05	0.249	75	825	1292	7.05	47	1.5	2350
Dextromethorphan	10	2.5	0.05	0.249	10	980	1262	7.05	47	1.5	2350
Menthol	10	2.5	0.05	0.249	10	980	1262	7.05	47	1.5	2350
Phenylpropanolamine	12.5	2.5	0.05	0.249	10	978	1262	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Tripolidin e HCl	Glycero l (ml)	Liquid Sucrose (ml)	Hydroxyeth ylcellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobroml de	Colour	Water
Ambroxol	30	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Guaiphenesin	100	2.5	0.8	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Dextromethorphan	10	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Menthol	10	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Phenylpropanolamine	12.5	2.5	0.95	2.95	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml

Upper Respiratory

Tablet formulae (mg/tab)

		Tripolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29- 32	Tablet
--	--	-----------------	---------	--------------------------------	--------------	-----------	-----------------------	----------------------	--------

Lozenge Formulae (mg/loz)

	Tripolidine HCl	Tripolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	Lozenge wt (mg)
Benzocaine	10	2.5	0.05	0.249	10	980	1262	7.05	47	1.5	2350
Lignocaine	10	2.5	0.05	0.249	10	980	1262	7.05	47	1.5	2350
Hexylresorcinol	2.5	2.5	0.05	0.249	10	987.5	1262	7.05	47	1.5	2350
Tyrosine	1	2.5	0.05	0.249	10	989	1262	7.05	47	1.5	2350
Dichlorobenzyl alcohol	1.2	2.5	0.05	0.249	10	988.8	1262	7.05	47	1.5	2350
Amyl methyl cresol	0.6	2.5	0.05	0.249	10	989.4	1262	7.05	47	1.5	2350
Cetyl pyridinium chloride	2	2.5	0.05	0.249	10	988	1262	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Tripolidine HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxyethyl cellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromi de	Colour	Water
Benzocaine	10	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25		to 5ml
	10	2.5	0.8	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Lignocaine														
Hexylresourcinol	2.5	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Tyrothricin	1	2.5	0.99	2.99	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Dichlobenzyl alcohol	1.2	2.5	0.95	2.95	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Amyl methyl cresol	0.6	2.5	1.0	3.0	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml
Cetyl pyridinium chloride	2	2.5	0.99	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25	0.9	to 5ml

Anxiety

Tablet Formulae (mg/tab)

		Triprolidine HCl	Lactose	Pregelatinised Maize Starch	Maize Starch	Ac-di-sol	Magnesium Stearate	Plasdone K-29-32	Tablet wt (mg)
Propanolol	10	2.5	185.5	12	48	25	2	15	300
Propanolo	20	2.5	175.5	12	48	25	2	15	300
Propanolol	40	2.5	155.5	12	48	25	2	15	300

Lozenge Formulae (mg/loz)

		Triprolidine HCl	Aerosil	Magnesium stearate	Calcium Carbonate	Liquid Glucose (sol contents)	Liquid Sugar (sol contents)	Flavour	Water (ml)	Plasdone K29-32	Lozenge wt (mg)
Propanolol	10	2.5	0.05	0.249	10	980	1262	7.05	47	1.5	2350
Propanolo	20	2.5	0.05	0.249	10	970	1262	7.05	47	1.5	2350
Propanolol	40	2.5	0.05	0.249	10	950	1262	7.05	47	1.5	2350

Syrup Formulae (mg/5ml)

		Tripolid Ine HCl	Glycerol (ml)	Liquid Sucrose (ml)	Hydroxyethyl cellulose	Citric Acid	Sodium Citrate	Sodium Saccharin	Flavour (ml)	Ethanol 96% (ml)	Levo - menthol	Domiphen Hydrobromide	Colour	Water
Propanolol	10	2.5	0.9	3.0	12.5	17	50	12.5	0.009	0.1	1	0.25		
Propanolol	20	2.5	0.9	2.9	12.5	17	50	12.5	0.009	0.1	1	0.25		
Propanolol	40	2.5	0.9	2.8	12.5	17	50	12.5	0.009	0.1	1	0.25		

Triprolidine was also prepared for the purposes of the clinical study as follows.

5 Clinical Example 1

Example 1 was produced in accordance with the following composition and constituted the trial formulation unless otherwise mentioned hereinafter. Patients received one
10 tablet for the 2.5mg dose and two tablets for the 5.0mg dose.

	<u>Name of Ingredient</u>	<u>mg/tablet</u>
	1. Triprolidine HCl. H ₂ O	2.5
15	2. Micro-crystalline Cellulose	29.0
	3. Lactose H ₂ O	60.0
	4. Magnesium Stearate	1.0
	5. Croscarmellose Sodium	10.0

20

Method

(a) Triprolidine hydrochloride (1) was mixed with approximately one-half of the components (2)-(5) and
25 thoroughly mixed. The remainder of components (2)-(5) were added and mixing continued to achieve uniform distribution of the active ingredient in the mixture.

(b) The mixture was compressed to form tablets, each
30 containing 2.5mg of active ingredient, in a tablet forming machine.

Clinical Trial

The efficacy of triprolidine in enabling a patient to feel refreshed or alert upon waking after taking triprolidine prior to sleeptime was investigated using patients with a history of sleep disorders and utilising triprolidine prepared in accordance with example 3.

The study herein utilised the following determination methods:-

(a) Karolinska scale as defined in: Int. J. Neuroscience 52 29-37 (1990); and

- validation: Sleep 17 (3) 236-41 (1994)

(b) Loughborough Sleep log as defined in : Sleep 17 (2) 146-159 (1994); and

Sleep 18 (2)

127-134 (1995)

(c) Actimetry - AW4 actimeters (Cambridge Neurotechnology) were worn continuously throughout the study. A button was pressed at night when the subject desired to go to sleep and again in the morning upon waking. The results of the actimeter study were analysed in the manner defined by Horne et al (Sleep, 17(2); 146-159).

SDI% was calculated as follows:-

$$\text{SDI} = \frac{\text{Number of 30 second epochs with movement}}{\text{Number of 30 second epochs from total time spent in bed}} \times 100$$

This is the measure of:

1. The length of time it took to fall asleep
 2. Any awakenings throughout the sleep period
- Expressed as a % of total time spent in bed.

Study Objectives

- To evaluate the effects of two doses of triprolidine compared with placebo.

Study Design

A multiple-dose, placebo-controlled, parallel-group, double-blind, randomised study investigating the effects of 2.5mg and 5mg triprolidine in patients with temporary sleep disturbance.

Male and Female candidates aged 18 years and above were recruited to one of five research centres by means of local advertising. Candidates were screened by means of a telephone questionnaire and selected candidates invited for interview at the research centre. Key inclusion criteria used to select candidates for the study were:

- A record of poor sleep at least 2 nights per week
- A record of poor sleep for at least 1 week but not more than 3 months
- Sleep disturbance not caused by underlying disease
- No excess use of alcohol or drugs
- Sleep disturbance affected daytime functioning

The candidates came to the research centre on Thursday or Friday and were fitted with a wrist actimeter (AW4 from Cambridge Technology) to establish a baseline measure for SDI and were provided with diary cards to record subjective assessments for the Loughborough Sleep Log and the Karolinska Sleepiness Scale. They returned to the investigational site on the Monday and were issued with the study compositions (2.5mg triprolidine, 5mg triprolidine or placebo). The investigator telephoned a

central randomisation centre where the subject was randomised to a particular treatment group using a dynamic balanced randomisation algorithm. The subject was given three doses of their allocated study medication and
5 instructed to take a single dose of two tablets 20 minutes before they intended to go to sleep on three consecutive evenings, commencing that evening. The diary cards for the Loughborough Sleep Log and Karolinska Sleepiness Scale were asked to be completed on waking.

10

The candidates returned to the research centre on the following Friday.

Parameters Evaluated

15

Candidates were required to complete a questionnaire 15 minutes after awaking on the feeling of refreshedness assessed on a 5-point scale, the Loughborough sleep log.

20 A daytime sleepiness assessment was also made 20 minutes, 2 hours and 4 hours after awaking on the Karolinska 9-point scale, i.e. the sleepiness scale.

Results

25

198 candidates completed the study, of whom 178 provided valuable data. (61 placebo, 60 on 2.5mg triprolidine and 57 on 5mg triprolidine. The subjects on 2.5mg dose took one tablet and placebo those on 5mg dose took 2x2.5mg
30 tablets. The subjects on placebo took a dose to match the active treatments (2 tablets).

Key results were as follows:

- 35 • There was evidence that there was a lack of daytime sleepiness associated with those patients who took either dose of triprolidine

- The SDI was reduced for both treatments as compared with placebo on every treatment night
- The sleep latency onset was reduced for both treatments as compared with placebo on every treatment night

5

The following results were obtained for patients taking 2.5mg triprolidine. For the mean of the 3 nights:

- 10 • 15 minutes after waking, patients taking triprolidine recorded feeling more refreshed than those on placebo, as determined by the Loughborough sleep log($p < 0.05$).
- 15 • There were a greater percentage of people on 2.5mg triprolidine who, on waking were feeling alert, very alert or extremely alert than those on placebo as measured by the Karolinska log.
- 20 • There was a lower percentage of people on 2.5mg triprolidine who, on waking were feeling sleepy, and needing to make some effort or very sleepy, needing to make a great effort to keep awake than those on placebo as measured by the Karolinska log.
- There was no evidence of residual hangover effects / morning grogginess from the drug.
- The SDI was significantly reduced compared to those on placebo ($p < 0.01$).
- 25 • The sleep latency onset was reduced as compared to those on placebo ($p < 0.05$).

30 Further analyses show the advantageous effects of triprolidine in relation to the degree of refreshedness on waking.

The study design used 3 groups. On average, the number of individuals in each of the 3 groups (placebo, 2.5mg triprolidine and 5mg triprolidine) was 60 ± 10 patients.

35

In the trial, patients were tested during a seven day period and the results have been analysed for a mean of three days in the middle of this period. The effects of triprolidine at dose level 2.5mg and 5.0mg are compared
5 with placebo in table 1.

Table 1

Datasets (a) to (g) - Main Analyses

5

		Placebo	2.5mg	5mg
(a) SDI (%)		Mean	Mean	Mean
(Sleep latency onset and	Mon	13.19	11.33	11.72
Quality of sleep)	Tues	14.58	12.15	12.71
(Actimeter)	Wed	14.46	11.2	11.81
	Mean of 3	14.26	11.56	12.23
(b) TTSO (min)		Mean	Mean	Mean
(Time to Sleep onset)	Mon	20.75	16.22	16.16
(Actimeter)	Tues	22.29	15.62	17.88
	Wed	20.26	14.8	16.36
	Mean of 3	22.16	15.53	16.93
(c) 15mins after awaking		Mean	Mean	Mean
(1- very refreshed	Mon	3.41	3.33	3.72
5- very tired)	Tues	3.46	3.23	3.56
(Loughborough sleep log)	Wed	3.42	3.18	3.54
	Mean of 3	3.45	3.24	3.59

		Placebo	2.5mg	5mg
	Mean of 3			
(d) last night I slept		Mean	Mean	Mean
1- extremely well,	Mon	3.2	2.67	2.49
5- extremely badly)	Tues	3.06	2.71	2.93
(Loughborough sleep log)	Wed	3.02	2.81	2.64
	Mean of 3	3.11	2.73	2.69
(e) time to fall asleep (min)		Mean	Mean	Mean
(Loughborough sleep log)	Mon	33.61	23.67	22.02
	Tues	29.73	24.44	32.08
	Wed	28.35	20.95	24.24
	Mean of 3	30.98	23.93	26.5
(f) no of times woke up		Mean	Mean	Mean
(Loughborough sleep log)	Mon	1.9	1.18	1.49
	Tues	1.61	1.37	1.42
	Wed	1.43	1.11	1.39
	Mean of 3	1.71	1.22	1.42

Statistical Analysis

Generally the treatment groups were well balanced in terms
 5 of the demographic data. Unless otherwise mentioned all
 group data was analysed using ANOVA. In two cases,
 namely, how the patient felt 15 minutes after awakening in
 the Loughborough Sleep Log and the Karolinska Sleepiness
 Scale at 20 minutes, the two variables were analysed using
 10 ANCOVA by including the weekend and the mean of
 Friday/Saturday/Sunday night as a covariate. The method
 was a closed test procedure (Williams' test). Each of the
 tests were to be conducted at the 5% level. The analysis
 of the secondary endpoints was similarly conducted using
 15 the Student's t-tests on parameter estimates taken from
 the analysis of variance model presented above.

The following is a copy of the "Loughborough sleep log
 questionnaire" which was used by patients in the study
 20 and provided the data for datasets a and b in table 1.

"Loughborough Sleep Log" Questionnaire

This will be completed 15 minutes after waking.

25 Bedtime Log

I went to bed at: I turned out the lights at:

The windows are: shut Not shut

30 Morning Log

I woke up at this morning I got out of bed at
 this morning

15 minutes after waking I felt:

Last night I slept:

35 a) very refreshed a) extremely well
 b) refreshed b) very well

c) neither refreshed nor tired	c) fairly well
d) tired	d) rather badly
e) very tired	e) extremely badly

5 Night Diary

During the night the windows were left: opened
shut

During the night the secondary glazing was left:
10 opened shut

During the night my partner slept in:
the same bed as me a different bed to me
As far as I can remember, it took me minutes to fall
15 asleep last night

As far as I can remember, I woke up times last night
Please note the details of any awakenings you can remember
in the table below.

Time	Length of time awake (mins)	Reason for
20 awakening."		

Table 2 shows additional data in connection with data set
(a) showing the improvement in refreshed responses at the
2.5mg dosage of triprolidine hydrochloride monohydrate.

Table 2
Loughborough Sleep Log: Awoke Very Refreshed or Refreshed Responses

Day of Testing	Monday		Tuesday		Wednesday	
	N	%	n	%	n	%
Dose						
Placebo	10	15.2	10	16.4	11	18.3
2.5mg TRP.HCl.H ₂ O	14	23	14	23	16	25.8
5mg TRP.HCl.H ₂ O	7	11.5	5	8.2	9	14.8

Similarly, table 3 shows corresponding additional data in connection with data set (b).

Table 3
Loughborough Sleep Log: Last Night I Slept Extremely Well or Very Well Responses

Day of Testing	Monday		Tuesday		Wednesday	
	N	%	n	%	n	%
Dose						
Placebo	11	18	12	22.2	13	24.1
2.5mg TRP.HCl.H ₂ O	24	41.4	23	41.8	22	37.9
5mg TRP.HCl.H ₂ O	30	50.9	17	28.8	24	39.3

Karolinska's sleepiness scale is set out below and the results for placebo, 2.5 and 5.0mg doses of triprolidine are shown in tables 4 and 5. Table 4 relates to the number of individuals experiencing scales 1, 2 or 3 on the Karolinska scale and table 5 relates to the number of individuals experiencing scales 8 and 9.

Karolinska Sleepiness Scale

This will be completed 20 minutes after awakening and then at 2 hours and 4 hours following the first assessment on days 5, 6, 7 and 8.

- | | | |
|----|----|---|
| 15 | 1. | Extremely alert |
| | 2. | Very alert |
| | 3. | Alert |
| | 4. | Rather alert |
| | 5. | Neither sleepy or alert |
| | 6. | Some signs of sleepiness |
| 20 | 7. | Sleepy but no effort to keep awake |
| | 8. | Sleepy, some effort to keep awake |
| | 9. | Very sleepy, Great effort to stay awake, fighting sleep |

Table 4

Karolinska 9-point scale

(a) I feel extremely alert, very alert or alert

Day of Testing	Monday		Tuesday		Wednesday	
	n	%	n	%	n	%
Dose						
Placebo	9	13.6	14	23.0	11	17.2
2.5mg TRP.HCl.H ₂ O	13	21.3	13	21.3	13	21.0
5mg TRP.HCl.H ₂ O	4	6.3	6	9.5	11	17.5

Table 5

(b) I feel (i) sleepy, [and need to make] some effort or (ii) very sleepy, a great effort to keep awake

Day of Testing	Monday		Tuesday		Wednesday	
	n	%	n	%	n	%
Dose						
Placebo	8	12.1	10	16.4	9	14.1
2.5mg TRP.HCl.H ₂ O	7	11.5	8	13.1	4	6.5
5mg TRP.HCl.H ₂ O	8	12.5	11	17.5	8	12.7

The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this
5 specification, and the contents of all such papers and documents are incorporated herein by reference.

All of the features disclosed in this specification (including any accompanying claims, abstract and
10 drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

15 Each feature disclosed in this specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each
20 feature disclosed is one example only of a generic series of equivalent or similar features.

The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any
25 novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

Claims

- 5 1. The use of triprolidine or a salt or hydrate thereof,
in combination with at least one further active
pharmaceutical agent, as active ingredient of an aid to
waking refreshed after sleeping.
- 10 2. The use of triprolidine or a salt or hydrate thereof,
in combination with at least one further active
pharmaceutical agent, as active ingredient for the
preparation of a composition for enabling an individual
to wake refreshed after sleeping.
- 15 3. The use of triprolidine or a salt or hydrate thereof,
in combination with at least one further active
pharmaceutical agent, as active ingredient for the
preparation of a medicament for enabling an individual
20 to wake refreshed after sleeping.
4. The use of triprolidine or a salt or hydrate thereof,
in combination with at least one further active
pharmaceutical agent, for the preparation of a sleep
25 aid which also enables an individual to wake refreshed
after sleeping.
5. The use of triprolidine or a salt or hydrate thereof,
in combination with at least one further active
30 pharmaceutical agent, as active ingredient of a sleep
aid which also enables an individual to wake refreshed
after sleeping.
6. The use of triprolidine or a salt or hydrate thereof,
35 in combination with at least one further active
pharmaceutical agent, as active ingredient for the
preparation of a medicament for the treatment or

prevention of a sleep disorder which also enables an individual to wake refreshed after sleeping.

- 5 7. Use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders.
- 10 8. The use of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for inducing, prolonging and/or enhancing sleep and/or sleep quality.
- 15 9. A method for the treatment or prevention of grogginess, drowsiness or lethargy on waking from sleep in a mammal comprising the administration to the mammal in need thereof of a non-toxic effective dose of triprolidine or a salt or hydrate thereof in combination with at least one further active pharmaceutical agent prior to the desired sleeping time.
- 20 10. A method for enabling an individual to wake refreshed after sleeping comprising the administration to the individual in need thereof and prior to the desired sleeping time of a non-toxic effective dose of triprolidine or a salt or hydrate thereof in combination with at least one further active pharmaceutical agent.
- 30 11. A method for aiding an individual's sleep and for also enabling the individual to subsequently wake refreshed after sleeping comprising the administration to the individual in need thereof and prior to the desired sleeping time of a non-toxic effective dose of triprolidine or a salt or hydrate thereof in
- 35

combination with at least one further active pharmaceutical agent.

- 5 12. A method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an effective dose of triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient to such a person.
- 10 13. A method for inducing, prolonging and/or enhancing sleep, which method comprises administration of an effective dose of triprolidine or a salt or hydrate thereof, in combination with at least one further
- 15 active pharmaceutical agent, as active ingredient to a person desirous of achieving sleep.
- 20 14. A waking refreshed aid comprising triprolidine or a salt or hydrate thereof, in combination with at least one further active pharmaceutical agent, as active ingredient in association with a pharmaceutically acceptable carrier therefor and instructions for administration thereof at or just before the desired sleeping time.
- 25 15. A pharmaceutical formulation for the treatment or prevention of grogginess, drowsiness or lethargy on waking after sleeping, comprising triprolidine or a salt or hydrate thereof, in combination with at least
- 30 one further active pharmaceutical agent, as active ingredient in association with a pharmaceutically acceptable carrier therefor and instructions for administration thereof at or just before the desired sleeping time.
- 35 16. A pharmaceutical formulation for enabling an individual to wake more refreshed after sleeping,

comprising triprolidine or a salt or hydrate thereof,
in combination with at least one further active
pharmaceutical agent, as active ingredient in
association with a pharmaceutically acceptable carrier
5 therefor and instructions for administration thereof at
or just before the desired sleeping time.

17. The use of triprolidine or a salt or hydrate thereof
as claimed in any of claims 1 - 8, wherein the said at
10 least one further active pharmaceutical agent is
intended to be used in the treatment of a condition
having sleep disorder as a symptom or potential
symptom.

15 18. The use of triprolidine or a salt or hydrate thereof
as claimed in any of claims 1 - 8 or 17, wherein the
said at least one further active pharmaceutical agent
is selected from: an active agent used in the treatment
of pain relief, migraines, allergies, colds, flu,
20 coughs or anxiety; an active agent used as an
anaesthetic, antiviral agent, antidepressive agent,
decongestant or disinfectant; or an active agent used
in women's health

25 19. The use of triprolidine or a salt or hydrate thereof
as claimed in any of claims 1 - 8 or 17-18, wherein the
said at least one further active agent is independently
selected from any one or more of the following agents
or their active salts or hydrates: Ibuprofen,
30 Fluribiprofen, Ketoprofen, Aspirin, Paracetamol,
Aceclofenac, Codeine, Naproxen, Indomethacin,
Diclofenac, Cox II, Meloxicam, Nitric oxide, Caffeine,
Acrivastine, Cetirizine, Loratadine, Fexofenadine,
Terfenadine, Beclomethasone, Hydrocortisone, Triptan,
35 Almotriptan, Rizatriptan, Naratriptan, Sumatriptan,
Zolmatriptan, Domperidone, Acetylcysteine, Menthol,
Ambroxol, Carbocisteine, Dextromethorphan,

Guaiphenesin, Ipecacuanha, Phenylpropanolamine,
Liquorice, Marshmallow, Squill, Honey, Glycerine,
Aniseed, Benzocaine, Lidocaine, Amantadine, Aciclovir,
Famciclovir, Ganciclovir, Rimantadine, Penciclovir,
5 Tribavirin, Valaciclovir, Neuraminidase inhibitors,
Zanamir, Oseltamir, Benzalkonium chloride,
Cetylpyridinium chloride, Dichlorobenzyl alcohol,
Amylmetacresol, Dequalinium chloride, Hexylresorcinol,
Eucalyptus oil, Thymol, Calamine, Propranalol,
10 Chamomile, Hops, Passion flower, Valarian, Melatonin,
Eucalyptus, Phenylephrine, Pseudoephedrine, Cranberry
and Bisphosphonates.

20. The use of triprolidine as a salt or hydration thereof
15 as claimed in any of claim 19, wherein the said active
pharmaceutical agent is independently selected from any
one or more of the following agents or their active
salts or hydrates Ibuprofen, Fluribiprofen, Cox II such
as meloxicam, triptans, Domperidone, Ambroxol,
20 Dextromethorphan, Guaiphenesin, Lidocaine, Amantadine,
Hexylresorcinol, dcba, amc, Propranalol,
pseudoephedrine and Bisphosphonates or a
pharmaceutically acceptable salt of any of the
foregoing.

25

21. The use of triprolidine or a salt or hydrate thereof
as claimed in any of claims 1 - 8 or 17-20, wherein the
further active pharmaceutical agent may be combined
with triprolidine in a single dosage form or in a
30 pharmaceutical pack containing at least two dose forms,
one being triprolidine and the other being the said
further active pharmaceutical agent.

35 22. The use of triprolidine or a salt or hydrate thereof
as claimed in any of claims 1 - 8 or 17-21, wherein the
said pack includes instructions on how to take the

combination of triprolidine with the said further agent.

23. The use of triprolidine or a salt or hydrate thereof
5 as claimed in any of claims 1 - 8 or 17-22, wherein the dosage of the said further pharmaceutically active agent is one suitable for the treatment selected.
24. The use as claimed in any of claims 1-8 or 17-23,
10 wherein the dose of triprolidine administered to the user prior to sleeptime is between 0.01mg and 20mg.
25. The use as claimed in any of claims 1-8 or 17-24,
15 wherein the dose of triprolidine administered to the user before sleeptime is up to 20mg.
26. The use as claimed in any of claims 1-8 or 17-25,
wherein the said further active pharmaceutical agent may include, without limitation, antacids, analgesics,
20 anti-inflammatories, antibiotics, laxatives, anorexics, antiasthmatics, antidiuretics, antiflatulents, antimigraine agents, antispasmodics, additional sedatives, antihyperactives, tranquilizers, antihistamines, decongestants, betablockers,
25 antidepressives, hormones and combinations thereof.
27. The use as claimed in any of claims 1-8 or 17-26,
wherein the said dosage forms may be combined into a combined dosage form for simultaneous administration.
30
28. The method as claimed in any of claims 9-13, wherein the dose of active ingredient of triprolidine administered is between 0.01 and 20mg.
- 35 29. The method as claimed in any of claims 9-13 wherein the dose of active ingredient of triprolidine administered is up to 20mg.

30. The pharmaceutical formulation as claimed in any of claims 15 or 16, wherein the instructions for administration instruct a single dose comprising active ingredient of triprolidine of up to 20mg prior to sleeptime.
31. The pharmaceutical formulation as claimed in any of claims 15 or 16, wherein the instructions for administration instruct a single dose comprising active ingredient of triprolidine of between 0.01 and 20mg prior to sleeptime.
32. A waking refreshed aid as claimed in claim 14, wherein the instructions for administration instruct a single dose of the triprolidine active ingredient of up to 20mg prior to sleeptime.
33. A waking refreshed aid as claimed in claim 14, wherein the instructions for administration instruct a single dose comprising the active ingredient triprolidine of between 0.01 and 20mg prior to sleeptime.
34. A method as claimed in any of claims 9-13, 28 or 29, wherein the triprolidine is in the form of triprolidine hydrochloride.
35. A method as claimed in any of claims 9-13, 28, 29 or 34, wherein the person is suffering from a sleep disorder.
36. A method as claimed in any of claims 9-13, 28, 29 or 34, wherein the person is not suffering from a sleep disorder but is desirous of achieving a feeling of waking refreshed upon waking.

37. A method as claimed in any of claims 9-13, 28, 29 or 34-36, wherein the active ingredients are administered orally, nasally, optically, rectally, pulmonarily, transdermally or sub-lingually.
- 5
38. A method as claimed in claim 9-13, 28, 29 or 34-37, wherein the active ingredients are administered in the form of a tablet, capsule, drink, lozenge, drops, emulsion, dry powder, suspension, pastille, patch, 10 suppository, syrup, consumable film such as a buccal wafer, sub-lingual spray or nasal spray.
39. A method as claimed in any one of claims 9-13, 28, 29, 34-38, wherein the active ingredients are administered 15 to the mucous membranes of the nasal cavity.
40. A method as claimed in any of Claims 9-13, 28, 29 or 34-39, wherein the active ingredients are administered as a solution or suspension spray or as a powder.
- 20
41. A method as claimed in any of claims 9-13, 19, 20 or 25-31 in which the active ingredients are administered between 1 minute and 2 hours prior to sleeptime.
- 25
42. Use as claimed in any of claims 1-8 or 17-25, wherein the triprolidine is in the form of triprolidine hydrochloride.
- 30
43. Use as claimed in any one of Claims 1-8, 17-25 or 42, wherein the composition is for oral administration.
- 35
44. Use as claimed in any of claims 1-8, 17-25, 42 or 43, wherein the composition is in the form of a tablet, capsule, drink, lozenge, drops, emulsion, dry powder, suspension, pastille, patch, suppository, syrup, consumable film such as a buccal wafer, sub-lingual spray or nasal spray.

45. Use as claimed in any one of Claims 1-8, 17-25 or 42, wherein the composition is for administration to the mucous membranes of the nasal cavity.
- 5 46. Use as claimed in any of Claims 1-8, 17-25 or 42, 43 or 45, wherein the composition is a solution or suspension or a powder.
- 10 47. The use as claimed in any of claims 1-8, 17-25, or 42-46, wherein the triprolidine forms the active ingredient of a formulation which contains a blend of two or more diluents, one of which may also serve as a disintegrant.
- 15 48. The use as claimed in any of claims 1-8, 17-25, 42, 43, 45 or 47, wherein the triprolidine forms the active ingredient of a formulation, which comprises a saccharide diluent.
- 20 49. The use as claimed in claim 48, wherein the triprolidine formulation further comprises a disintegrant.
- 25 50. The use as claimed in claim 49, wherein the triprolidine formulation further comprises the saccharide diluent and the disintegrant in the ratio of 1-10 parts by weight saccharide diluent to 1 part by weight of disintegrant.
- 30 51. The use as claimed in claim 49 or Claim 50, wherein the saccharide diluent is lactose, and the disintegrant is croscarmellose sodium.
- 35 52. The use as claimed in any one of Claims 47 to 51, wherein the triprolidine formulation further comprises a lubricant.

53. The use as claimed in claim 52, wherein the lubricant is magnesium stearate.

5 54. The use as claimed in any one of Claims 47 to 53, wherein the triprolidine formulation is formed with a coating of a hydrophilic polymer.

10 55. The use as claimed in claim 54, wherein the hydrophilic polymer is a methylated cellulose derivative.

15 56. The use as claimed in any one of Claims 47 to 55, which is free of ingredients intended or effective to sustain or prolong release of the active ingredients.

20 57. The use as claimed in any of claims 1-8, 17-25 or 42-56, wherein the dosage of the said further pharmaceutically active agent is one suitable for the treatment selected.

25 58. The use as claimed in any of claims 1-8, 17-25 or 42-57, wherein a single dosage form of said pharmaceutically active agent is in the range 0.1mg - 2000mg.

30 59. A method of manufacturing a formulation as claimed in any one of Claims 45 to 58, which involves direct compression of the ingredients into a tablet without an intermediate granulation stage.

35 60. The uses of triprolidine, in combination with a further active pharmaceutical agent, as hereinbefore described and with reference to the examples.

61. The methods for the treatment of grogginess as hereinbefore described and with reference to the examples.
- 5 62. The tablets as hereinbefore described and with reference to the examples.
63. The pharmaceutical formulations as hereinbefore described and with reference to the examples.
- 10 64. The waking refreshed aids as hereinbefore described and with reference to the examples.
- 15 65. The method for enabling an individual to wake refreshed after sleeping as hereinbefore described and with reference to the examples.
66. A waking refreshed aid as hereinbefore described and with reference to the examples.
- 20 67. A pharmaceutical formulation as hereinbefore described and with reference to the examples.
- 25 68. Use of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for the treatment of sleep disorders as hereinbefore described and with reference to the examples.
- 30 69. The use of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient in the manufacture of a composition for inducing, prolonging and/or enhancing sleep as hereinbefore described and with reference to the
- 35 examples.

70. A method of treating sleep of a person suffering from a sleep disorder, which method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient to such a person as hereinbefore described and with reference to the examples.

71. A method for inducing, prolonging and/or enhancing sleep, which method comprises administration of an effective dose of triprolidine, in combination with at least one further active pharmaceutical agent, as active ingredient to a person desirous of achieving sleep as hereinbefore described and with reference to the examples.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB2004/002330

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/44 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 245 785 B1 (NICHOLS W MICHAEL ET AL) 12 June 2001 (2001-06-12) column 1, lines 6-10	14-16, 30-33
X	US 3 146 169 A (JOHN SPENCE ET AL) 25 August 1964 (1964-08-25) column 1, lines 12,13 column 2, line 36	1-71
X	WO 03/032912 A (MIGNOT EMMANUEL J M ; HYPNION INC (US); EDGAR DALE M (US); HANGAUER DA) 24 April 2003 (2003-04-24) column 2, lines 3-13	1-71
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

14 October 2004

Date of mailing of the international search report

29/10/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31.651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heller, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/002330

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NETDOCTOR: "Actifed expectorant" 1998, XP002300836 Retrieved from the Internet: URL:http://www.netdoctor.co.uk/medicines/1 00000021.html> 'retrieved on 2004-10-06! the whole document -----	14-16, 30-33
X	DRUGS.COM: "Interactions and informations" 2001, XP002300837 Retrieved from the Internet: URL:http://www.drugs.com/alpha/t9.html> 'retrieved on 2004-10-06! the whole document -----	14-16, 30-33
P,X	US 2003/180352 A1 (CHEN FENG-JING ET AL) 25 September 2003 (2003-09-25) column 1, paragraph 3 column 3, paragraph 46 -----	1-71

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2004/002330

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1, 9-13, 17-29, 34-61, 70, 71
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB2004/002330

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6245785	B1	12-06-2001	AU	5915899 A	19-06-2000
			WO	0032173 A1	08-06-2000
<hr/>					
US 3146169	A	25-08-1964	GB	972128 A	07-10-1964
			DE	1127542 B	12-04-1962
			FR	1311119 A	07-12-1962
<hr/>					
WO 03032912	A	24-04-2003	CA	2463579 A1	24-04-2003
			EP	1443929 A2	11-08-2004
			WO	03032912 A2	24-04-2003
			US	2003187021 A1	02-10-2003
			US	2004142972 A1	22-07-2004
<hr/>					
US 2003180352	A1	25-09-2003	US	2003064097 A1	03-04-2003
			US	6248363 B1	19-06-2001
			US	2003077297 A1	24-04-2003
			US	2003215496 A1	20-11-2003
			AU	1798101 A	04-06-2001
			CA	2391923 A1	31-05-2001
			EP	1233756 A1	28-08-2002
			JP	2003517470 T	27-05-2003
			WO	0137808 A1	31-05-2001
<hr/>					